SND-631

SND-631 is a **preclinical small-molecule GPX4 modulator** reported to be developed by **Floratek Pharma**. Publicly accessible drug-intelligence aggregators describe it as a first-in-class program directed at **glutathione peroxidase 4**, with development activity reported in oncology indications including **pancreatic cancer**, **lung cancer**, and **ovarian cancer**. The exact pharmacology is not well characterized in openly available primary-source materials, so the specific direction of modulation, binding mode, and downstream ferroptosis biology should be treated as insufficiently disclosed in public sources at present.